5 Reasons Peptide Programs Stall Before the Molecule Does

...and how recombinant production changes the equation

The Pressure on Peptide and Protein Manufacturing Today

The peptide therapeutics market is surging. GLP-1 receptor agonists alone have reshaped global manufacturing demand, and behind them sits a pipeline of antimicrobial peptides, pepteins (41 to 200 amino acids), complex disulfide-rich targets, and next-generation biologics that all need a viable production route. For CMC, process development, and procurement teams, the question is no longer whether peptides will be central to the pipeline. It is whether the manufacturing infrastructure can keep up.

Teams that stay locked into chemical synthesis face compounding pressure: rising raw material costs, tightening environmental regulation, upstreaming and downstreaming bottlenecks that erode margins, and a global capacity crunch that is getting worse, not better.

In this environment, teams need a production platform that removes these constraints. Numaferm's Numaswitch platform is a recombinant E. coli-based biochemical production system for peptides, pepteins, and proteins from 2 to 1000+ amino acids:

- Yields up to record-breaking 27 g/L with API quality from a single chromatographic step
- Milligram samples in ~4 weeks, gram-scale in 2 months, cGMP/kg-scale in ~6 months
- Water-based process: no DMF, no TFA, no organic solvents
- 500+ successful projects delivered across therapeutic, industrial, and veterinary applications

THE 5 CHALLENGES

Where Peptide Programs Run Into Trouble

1 Your Peptide Works at 20 Amino Acids. At 40, the Chemistry Stops Working.

Solid-phase peptide synthesis performs reliably for short sequences, typically up to 30 amino acids. Beyond that length, yields drop, deletion sequences accumulate, and crude purity falls sharply. For pepteins in the 41 to 200 amino acid range, chemical synthesis is either prohibitively expensive or functionally impossible.

TRADITIONAL APPROACH:

Fragment condensation or native chemical ligation can extend the range of SPPS, but each additional fragment adds development time, cost, and yield loss.

NUMASWITCH ADVANTAGE:

Handles targets from 2 to 1000+ amino acids using a standardized workflow. Proprietary Switchtag proteins enable high-titer production regardless of sequence length, including disulfide-rich targets such as venom peptides, antibody fragments, cytokines, and growth factors.

2 The Solvents That Make Your Process Run Are the Same Ones Regulators Want Gone.

Every SPPS workflow depends on DMF, TFA, and organic solvents for coupling, deprotection, and cleavage. EU REACH restrictions on DMF are already tightening, ESG reporting is expanding, and pharma companies face increasing pressure to demonstrate greener manufacturing. For procurement and CMC teams, this is a compliance risk affecting site selection, sourcing, and regulatory filings.

TRADITIONAL APPROACH:

Solvent recycling and substitution programmes reduce waste volume but cannot eliminate the dependence on hazardous chemicals in SPPS.

NUMASWITCH ADVANTAGE:

The entire production process is water-based. No DMF, no TFA, no organic solvents at any stage. Simplifies environmental compliance and eliminates solvent-related safety infrastructure.

3 Purification Is Costing You More Than the Synthesis Itself.

SPPS crude purity typically sits in the 70 to 80% range. The remaining 20 to 30% consists of deletion sequences, truncations, racemization byproducts, and residual protecting group fragments requiring extensive RP-HPLC. For longer peptides, crude purity drops further and the purification burden grows disproportionately. It is the purification, more so than the synthesis, that defines your cost per gram.

TRADITIONAL APPROACH:

Multi-step RP-HPLC with decreasing yields at each stage. Scaling purification capacity requires dedicated equipment and significant capital investment.

NUMASWITCH ADVANTAGE:

High-density production effectively segregates impurities during fermentation. Single batches in the tons scale are accessible. The proprietary Switchtag-mediated refolding step selectively purifies the target, and minimal impurity profiles enable a single chromatographic polishing step, delivering greater than 98% purity routinely.

4 Every Amino Acid You Add Compounds Your Cost-of-Goods.

In chemical synthesis, cost scales exponentially with chain length. Every additional amino acid coupling adds protected amino acid reagent costs, extends cycle time, and reduces cumulative titer. The GLP-1 manufacturing surge has driven up protected amino acid prices and extended raw material lead times. For 30+ amino acid targets, the economics of SPPS are moving in the wrong direction.

TRADITIONAL APPROACH:

Improved coupling chemistry and reagent sourcing reduce unit costs marginally, but the fundamental non-linear cost scaling with sequence length remains a challenge.

NUMASWITCH ADVANTAGE:

Recombinant fermentation decouples cost from sequence length. A 15-amino acid peptide and a 200-amino acid protein are produced at comparable cost per gram. Final API-grade yields of 27 g/L combined with single-step purification deliver economics that outperform alternatives significantly.

5 The CDMO Slot You Need in 2027 Was Booked in 2025.

Global SPPS capacity is finite and increasingly concentrated. The GLP-1 boom has absorbed reactor time at every major peptide CDMO, and smaller programmes compete for the same slots as billion-dollar franchises. For clinical-stage programmes on a regulatory timeline, a delayed manufacturing slot can mean a delayed IND filing, reducing the program value eventually dramatically.

TRADITIONAL APPROACH:

Booking capacity further in advance, accepting longer lead times, or paying premium rates for expedited slots.

NUMASWITCH ADVANTAGE:

Numaswitch uses standard bioreactor infrastructure available at CDMOs worldwide, not specialised SPPS reactors. Numaferm's CMO partner network (including Northway Biotech, Richter-Helms, Olon and others) provides access to established GMP fermentation capacity. Timeline from sequence to cGMP/kg-scale is as short as 6 months.

What Changes When You Get the Production Route Right

Teams that address manufacturing constraints early gain a structural advantage that compounds over the life of a programme. Lower cost-of-goods improves margins from preclinical through commercial. A cleaner process simplifies regulatory filings and site transfers. Access to fermentation capacity, rather than competing for saturated SPPS slots, protects clinical timelines.

Numaferm has delivered over 500 projects across peptides, pepteins, and proteins for biotech, pharma, and veterinary clients. The Numaswitch platform handles the full range from discovery through commercial production, on a single standardized workflow that does not reset with each new sequence. This reduces transfer friction and upscaling burdens.

If your team is evaluating production routes for a peptide, peptein, or protein asset, considering Numaferm and the biochemical production platform Numaswitch is a practical next step.

Learn More

Numaswitch Platform: numaferm.com/numaswitch
Case Studies & Publications: numaferm.com/news
Order Numacut TEV Protease: numaferm.com/numacut

Contact

Christian Schwarz, CEO
info@numaferm.com
numaferm.com